Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

Summary

This research study is being conducted in the U.S. and Europe to evaluate the safety and efficacy of daclizumab for the treatment of multiple sclerosis (MS).

Conditions

• Multiple Sclerosis

Interventions

DRUG

Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)

Sponsors & Collaborators

• PDL BioPharma, Inc.

  lead INDUSTRY

Principal Investigators

• Richard Dickson, M.D. · Wenatchee Valley Medical Center

• Steven Pugh, M.D. · Rockwood Clinic, PS

• Daniel Wynn, M.D. · Consultants in Neurology

• Theodore J. Phillips, M.D. · The MS Center at Texas Neurology

• Joanna Cooper · Sutter East Bay Medical Foundation

• James R. Storey · Upstate Clinical Research

• Malcolm Gottesman, M.D. · Winthrop University Hospital

• Herman Sullivan, M.D. · Michigan Medical P.C. Neurology

• Timothy Vollmer, M.D. · St. Joseph's Hospital and Medical Center, Phoenix

• Jeffery Dunn, M.D. · MS Hub Medical Group

• S. Mitchell Freedman, M.D. · Raleigh Neurology Associates

• Joseph Herbert, M.D. · Hospital for Joint Diseases, MS Care Center

• Omar Khan, M.D. · Wayne State University MS Center

• Marcelo Kremenchutzky, M.D. · London Health Sciences Centre

• Sharon Lynch, M.D. · CLMC Neurology

• Alireza Minagar, M.D. · Louisiana State University Health Sciences Center

• Jeffrey English, M.D. · The Multiple Sclerosis Center of Atlanta

• Andrew Goodman, M.D. · University of Rochester

• Michael Kaufman, M.D. · MS Center/CMC

• Florian P. Thomas, M.D. · St. Louis University Hospital

• Clyde Markowitz, M.D. · University of Pennsylvania

• Jayne Martin, M.D. · Michigan State University

• Maria Melanson, M.D. · Health Sciences Center

• MaryAnn Picone, M.D. · Gimble MS Center

• Christopher Bever, M.D · Maryland Center for MS

• Gregg G. Blevins, M.D. · University of Alberta

• Kasper Lloyd, M.D. · MS Center at Dartmouth

• Yves Lapierrre, M.D. · Montreal Neurological Institute

• John W. Rose, M.D. · University of Utah CAMT

• Michael Yeung, M.D. · Foothills Medical Centre

• Neil Lava, M.D. · Albany Medical College

• Jonathan L. Carter, M.D. · Mayo Clinic

• Francois Jacques, M.D. · Clinique SEP/NM

• William Honeycutt, M.D. · Neurology Associates, P.A.

• Istvan Pirko, M.D. · University of Cincinnati

• Ed Fox, M.D. · Central Texas Neurology

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

55 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2005-04-30

Completion

2006-10-31

Countries

• United States
• Canada

Study Locations